GH Research PLC (GHRS) Stock

GH Research PLC (GHRS) is a Healthcare stock trading at $22.22 (as of 2026-06-18), with a market capitalization of $1.56B and a trailing P/E of -28.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

GH Research PLC is a clinical-stage biopharmaceutical company developing therapies for psychiatric and neurological disorders, focused on 5‑MeO‑DMT for treatment-resistant depression. Its lead program GH001 is an inhalable product that has completed Phase 1 trials and a Phase 1/2 trial, with GH002 and GH003 in preclinical development.

Valuation — source: SEC EDGAR (first-party)
Price$22.22
Market Cap$1.56B
P/E Ratio-28.2
Price / Book4.93
DCF Value (model)$-11.45
DCF Upside vs Price-151.5%
Profitability & Growth — source: SEC EDGAR
Return on Equity-17.3%
Current Ratio34.13
Valuation vs Sector & Industry
Stock P/E-28.2
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-234.3%
vs Industry-263.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderLynx1 Capital Management LP ($151.33M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOVelichka Valcheva
Employees50
CountryIE
IPO Date2021-06-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Aquestive Therapeutics, Inc. (AQST)
  • Rigel Pharmaceuticals, Inc. (RIGL)
  • Spyre Therapeutics, Inc. (SYRE)
  • MapLight Therapeutics, Inc. (MPLT)
  • Anavex Life Sciences Corp. (AVXL)
  • Esperion Therapeutics, Inc. (ESPR)
  • Jade Biosciences, Inc. (JBIO)
GHRS earnings history · GHRS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.